jrnl3086

Publication Venue For

  • Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals.  105:1477-1491. 2019
  • Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis 2019
  • Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.  104:664-674. 2018
  • Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.  102:397-404. 2017
  • Precision Medicine at the University of Alabama at Birmingham: Laying the Foundational Processes Through Implementation of Genotype-Guided Antiplatelet Therapy.  102:493-501. 2017
  • Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait.  101:373-381. 2017
  • Pharmacokinetics, pharmacodynamics, and safety of lisinopril in pediatric kidney transplant patients: Implications for starting dose selection.  98:25-33. 2015
  • Helicase-primase as a target of new therapies for herpes simplex virus infections.  97:66-78. 2015
  • The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach.  96:380-389. 2014
  • Network medicine: Finding the links to personalized therapy.  94:613-616. 2013
  • Erratum: Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects (Clinical Pharmacology and Therapeutics (1995) 58 (44-53) DOI: 10.1016/0009-9236(95)90071-3).  89:320. 2011
  • Determination of appropriate dosing of influenza drugs in pediatric patients.  88:704-707. 2010
  • Treatment of herpes simplex virus infections in pediatric patients: Current status and future needs.  88:720-724. 2010
  • Erratum: Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects (Clinical Pharmacology and Therapeutics (2007) 82 (579-585) doi:10.1038/sj.clpt.6100208).  88:138. 2010
  • Integration of genetic, clinical, and INR data to refine warfarin dosing.  87:572-578. 2010
  • Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.  83:312-321. 2008
  • Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients.  83:281-287. 2008
  • New pre-pandemic influenza vaccines: An egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice.  82:665-671. 2007
  • Change in erythropoietin pharmacokinetics following hematopoietic transplantation.  81:873-879. 2007
  • Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation.  81:867-872. 2007
  • The role of public policy in treating the epidemic of global obesity.  81:772-775. 2007
  • Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects.  82:579-585. 2007
  • Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis.  72:546-555. 2002
  • Pharmacokinetic strategies for concentration-targeted therapy with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV).  65:161. 1999
  • Concentration-controlled zidovudine therapy.  64:331-338. 1998
  • Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects.  58:44-53. 1995
  • Linear single‐dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections.  53:15-21. 1993
  • Homocysteine levels in patients with rheumatoid arthritis treated with low‐dose methotrexate.  50:547-556. 1991
  • Pharmacokinetics of esmolol and ASL-8123 in renal failure.  45:321-327. 1989
  • Rapid development of enhanced clearance after high-dose cyclophosphamide.  44:622-628. 1988
  • Enalapril in low-renin essential hypertension.  34:297-302. 1983
  • Lofexidine and clonidine in moderate essential hypertension.  30:752-757. 1981
  • Plasma levels and urinary excretion of vidarabine after repeated dosing.  27:690-696. 1980
  • Acyclovir kinetics after intravenous infusion.  26:718-728. 1979